Discover 94 paid clinical trials in Huntsville, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 94
Featured
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
for
Chronic Migraine
Location: Huntsville AL, Nashville TN, Evansville IN,
Sponsor: AbbVie
Sex: All
Age: 12 - 17
Code: NCT06810505
Phase3, Recruiting
Featured
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
for
Migraine
Location: Huntsville AL, Nashville TN, Atlanta GA, Greenville SC,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05125302
Phase3, Recruiting
Featured
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
for
Episodic Migraine
Location: Huntsville AL, Nashville TN, Newburgh IN, Ridgeland MS,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05711394
Phase3, Recruiting
Featured
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
for
Breast Cancer
Location: Huntsville AL, Nashville TN, Atlanta GA, Charlotte NC,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT07100106
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
for
Obesity or Overweight, Type 2 Diabetes Mellitus
Location: Guntersville AL, Union City GA, Columbus GA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07351058
Phase3, Recruiting
Active & Responsive
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
for
Hyperphosphatemia,
Location: Huntsville AL, Dalton GA, Toledo OH, Kansas City MO,
Sponsor: R1 Therapeutics
Sex: All
Age: 18+
Code: NCT06712654
Phase2, Recruiting
Active & Responsive
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Location: Huntsville AL, Sheffield AL, Tullahoma TN, Canton GA,
Sponsor: Amgen
Sex: All
Age: 45 - 70+
Code: NCT07037433
Phase3, Recruiting
Active & Responsive
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
for
Heart Failure With Preserved Ejection Fraction,
Location: Huntsville AL, Tullahoma TN, Birmingham AL, Atlanta GA,
Sponsor: Amgen
Sex: All
Age: 18 - 70+
Code: NCT07037459
Phase3, Recruiting
Active & Responsive
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression